Impact of sodium-glucose transportation protein 2 inhibitor therapy on Diastolic hEart function and left AtriaL pressure in Atrial Fibrillation

Asan Medical Center0 个研究点目标入组 120 人开始时间: 待定最近更新: 2022年10月24日

适应症

试验速览

暂无简介。

•?Subjects with = 19 years of age
•?Documented atrial fibrillationon any form of electrocardiography.
•?Type 2 diabetes mellitus by American diabetic association diagnostic criteria (Fasting glucose=126mg/dL or 2-h PG=200mg/dL or HbA1C >6.5%)
•?HbA1C =7.5% before oral hypoglycemic agent or HbA1C 7.0-10.0% with one or more oral hypoglycemic agent (metformin or sulfonylurea)
•?Agreement with protocol and providing informed consent

•?Subject with conflict of interest
•?The subject who unable to provide informed consent or participating in the follow-up.
•?Prior use of sodium-glucose transport protein-2 inhibitor or Dipeptidyl peptidase-4 inhibitor
•?HbA1C = 10% or requiring insulin therapy for glucose management
•?Contraindications to the sodium-glucose transport protein-2 inhibitor or Dipeptidyl peptidase-4 inhibitor (hypersensitivity or Creatinine clearance < 30ml/min)
•?Active liver disease or laboratory abnormality (ALT or AST > x3 normal range)
•?Severe congestive heart failure (New York Heart associationClass III or IV)
•?Underlying conditions affect the primary outcome of the study (E/e') - Uncontrolled tachycardia, Mitral stenosis or regurgitation, prior mitral surgery, calcification of mitral annulus, left bundle branch block, aortic regurgitation
•?Active malignancy.
•?Pregnant and or lactating women
•?Life expectancy < 1 year
•? Not suitable for participation by the investigator's discretion

发起方